Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
CYTK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$32.74 - $68.44
Previous CloseN/A
Volume107.14K
Average Volume (3M)2.18M
Market Cap
$4.82B
Enterprise Value$5.27B
Total Cash (Recent Filing)$20.71M
Total Debt (Recent Filing)$724.00K
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 06, 2025EPS Estimate
-1.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.28
Shares Outstanding119,187,690
10 Day Avg. Volume1,873,335
30 Day Avg. Volume2,178,684
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)291.19
Price to Cash Flow (P/CF)-20.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit285.08
Enterprise Value/Ebitda-10.62
Forecast
1Y Price Target
$79.94Price Target Upside93.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
---
Cytokinetics News
PremiumStock Analysis & Ideas
Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThere is a high probability of a favorable outcome for the MAPLE-HCM trial based on the analysis of the statistical plan and prior data.
Market PotentialPositive data from MAPLE-HCM could help grow and expand the category as well as aficamten’s market share.
Bears Say
Commercial ChallengesThere are concerns about how payers might view aficamten data given the availability of generic beta-blockers, affecting commercial assumptions.
Safety And RestrictionsCamzyos label information still contains a Black Box Warning and is available only through a restricted REMS program.
---
Ownership Overview
0.80% Insiders
37.26% Mutual Funds
0.46% Other Institutional Investors
38.39% Public Companies and
Individual Investors
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $32.74 and its highest was $68.44 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $4.82B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is May 06, 2025 which is in 7 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Feb 27, 2025. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.193 by -$0.067.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.37.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 119,187,690 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.193. Following the earnings report the stock price went down -3.056%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
---
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.94 (93.93% Upside)
$79.94 (93.93% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 104.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.60%
12-Months-Change
Fundamentals
Return on Equity
435.49%
Trailing 12-Months
Asset Growth
70.04%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics (CYTK) is a late-stage biopharmaceutical company focused on the discovery and development of muscle biology-driven treatments for people with diseases characterized by impaired muscle function, muscle weakness, and muscle fatigue. Operating in the biotechnology and pharmaceutical sectors, the company is dedicated to advancing novel therapeutics for diseases such as amyotrophic lateral sclerosis (ALS), heart failure, and hypertrophic cardiomyopathy. Its core products are small molecule muscle activators and inhibitors targeting muscle contractility and performance.
---
CYTK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant regulatory progress and strategic partnerships for aficamten, a strong financial position, and pipeline advancements. However, increased expenses and ongoing regulatory challenges were noted. Despite these challenges, the progress and strategic moves position the company well for future growth.Read More>---
CYTK Stock 12 Month Forecast
Average Price Target
$79.94
▲(93.93% Upside)
Technical Analysis
---